These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 15899781

  • 1. HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses.
    Bhargava R, Lal P, Chen B.
    Am J Clin Pathol; 2005 Jun; 123(6):889-95. PubMed ID: 15899781
    [Abstract] [Full Text] [Related]

  • 2. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, Yin PL, Chen M.
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [Abstract] [Full Text] [Related]

  • 3. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    Scandinavian Breast Group Trial 9401Laboratory of Cancer Biology, Institute of Medical Technology, and Department of Oncology, Tampere University and Tampere University Hospital, Tampere, Finland., Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.
    J Clin Oncol; 2006 Jun 01; 24(16):2428-36. PubMed ID: 16682728
    [Abstract] [Full Text] [Related]

  • 4. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.
    Breast; 2008 Oct 01; 17(5):506-11. PubMed ID: 18456496
    [Abstract] [Full Text] [Related]

  • 5. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A.
    Hum Pathol; 2006 Oct 01; 37(10):1333-43. PubMed ID: 16949920
    [Abstract] [Full Text] [Related]

  • 6. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
    Tanner M, Järvinen P, Isola J.
    Cancer Res; 2001 Jul 15; 61(14):5345-8. PubMed ID: 11454672
    [Abstract] [Full Text] [Related]

  • 7. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.
    Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD.
    Clin Cancer Res; 2002 Apr 15; 8(4):1061-7. PubMed ID: 11948114
    [Abstract] [Full Text] [Related]

  • 8. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
    Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, Hellwig B, Rahnenführer J, Hengstler JG, Gehrmann MC.
    Clin Cancer Res; 2010 Apr 15; 16(8):2391-401. PubMed ID: 20371687
    [Abstract] [Full Text] [Related]

  • 9. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
    Engelstaedter V, Schiffers J, Kahlert S, Mainka P, Engel J, Kirchner T, Diebold J, Mayr D.
    Diagn Mol Pathol; 2012 Jun 15; 21(2):77-83. PubMed ID: 22555090
    [Abstract] [Full Text] [Related]

  • 10. Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification.
    Vranic S, Frkovic-Grazio S, Lamovec J, Serdarevic F, Gurjeva O, Palazzo J, Bilalovic N, Lee LM, Gatalica Z.
    Hum Pathol; 2010 Nov 15; 41(11):1617-23. PubMed ID: 20688355
    [Abstract] [Full Text] [Related]

  • 11. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
    Bhargava R, Naeem R, Marconi S, Luszcz J, Garb J, Gasparini R, Otis CN.
    Hum Pathol; 2001 Dec 15; 32(12):1344-50. PubMed ID: 11774167
    [Abstract] [Full Text] [Related]

  • 12. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K, Trojanec R, Kolár Z, Cwiertka K, Cernáková I, Mihál V, Hajdúch M.
    Neoplasma; 2006 Dec 15; 53(5):393-401. PubMed ID: 17013533
    [Abstract] [Full Text] [Related]

  • 13. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S.
    Cancer; 2005 Oct 01; 104(7):1391-7. PubMed ID: 16116605
    [Abstract] [Full Text] [Related]

  • 14. erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis.
    Lan C, Liu JM, Liu TW, Hsu DH, Liang S, Chen JR, Peng JW.
    Am J Clin Pathol; 2005 Jul 01; 124(1):97-102. PubMed ID: 15923160
    [Abstract] [Full Text] [Related]

  • 15. Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.
    Mano MS, Awada A, Di Leo A, Durbecq V, Paesmans M, Cardoso F, Larsimont D, Piccart M.
    Gynecol Oncol; 2004 Mar 01; 92(3):887-95. PubMed ID: 14984957
    [Abstract] [Full Text] [Related]

  • 16. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
    Mueller RE, Parkes RK, Andrulis I, O'Malley FP.
    Genes Chromosomes Cancer; 2004 Apr 01; 39(4):288-97. PubMed ID: 14978790
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
    Bhargava R, Lal P, Chen B.
    Am J Clin Pathol; 2005 Feb 01; 123(2):237-43. PubMed ID: 15842048
    [Abstract] [Full Text] [Related]

  • 19. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
    Shin SJ, Hyjek E, Early E, Knowles DM.
    Int J Surg Pathol; 2006 Oct 01; 14(4):279-84. PubMed ID: 17041191
    [Abstract] [Full Text] [Related]

  • 20. HER-2 amplification in tubular carcinoma of the breast.
    Oakley GJ, Tubbs RR, Crowe J, Sebek B, Budd GT, Patrick RJ, Procop GW.
    Am J Clin Pathol; 2006 Jul 01; 126(1):55-8. PubMed ID: 16753605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.